<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mult Scler J Exp Transl Clin</journal-id><journal-id journal-id-type="iso-abbrev">Mult Scler J Exp Transl Clin</journal-id><journal-id journal-id-type="publisher-id">MSO</journal-id><journal-id journal-id-type="hwp">spmso</journal-id><journal-title-group><journal-title>Multiple Sclerosis Journal - Experimental, Translational and Clinical</journal-title></journal-title-group><issn pub-type="epub">2055-2173</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28975037</article-id><article-id pub-id-type="pmc">5613850</article-id><article-id pub-id-type="doi">10.1177/2055217317727296</article-id><article-id pub-id-type="publisher-id">10.1177_2055217317727296</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Paper</subject></subj-group></article-categories><title-group><article-title>Effects of vitamin D<sub>3</sub> in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>O&#x02019;Connell</surname><given-names>Karen</given-names></name><xref ref-type="author-notes" rid="fn1-2055217317727296">*</xref><xref ref-type="corresp" rid="corresp1-2055217317727296"/></contrib><aff id="aff1-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff><aff id="aff2-2055217317727296">School of Medicine, University College Dublin, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sulaimani</surname><given-names>Jamal</given-names></name><xref ref-type="author-notes" rid="fn1-2055217317727296">*</xref></contrib><aff id="aff3-2055217317727296">School of Biochemistry and Immunology, Trinity College Dublin, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Basdeo</surname><given-names>Sharee A</given-names></name></contrib><aff id="aff4-2055217317727296">School of Biochemistry and Immunology, Trinity College Dublin, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Kinsella</surname><given-names>Katie</given-names></name></contrib><aff id="aff5-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Jordan</surname><given-names>Sinead</given-names></name></contrib><aff id="aff6-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Kenny</surname><given-names>Orla</given-names></name></contrib><aff id="aff7-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Siobhan B</given-names></name></contrib><aff id="aff8-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>David</given-names></name></contrib><aff id="aff9-2055217317727296">School of Medicine, University College Dublin, Ireland</aff><aff id="aff10-2055217317727296">Department of Radiology, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Heffernan</surname><given-names>Eric</given-names></name></contrib><aff id="aff11-2055217317727296">School of Medicine, University College Dublin, Ireland</aff><aff id="aff12-2055217317727296">Department of Radiology, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Killeen</surname><given-names>Ronan P</given-names></name></contrib><aff id="aff13-2055217317727296">School of Medicine, University College Dublin, Ireland Department of Radiology, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mulready</surname><given-names>Keith</given-names></name></contrib><aff id="aff14-2055217317727296">Department of Clinical Chemistry and Endocrinology, Mater Misericordiae University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>MacMahon</surname><given-names>Marguerite</given-names></name></contrib><aff id="aff15-2055217317727296">Department of Clinical Chemistry and Endocrinology, Mater Misericordiae University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Brady</surname><given-names>Jennifer J</given-names></name></contrib><aff id="aff16-2055217317727296">Department of Clinical Chemistry and Endocrinology, Mater Misericordiae University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>McKenna</surname><given-names>Carmel</given-names></name></contrib><aff id="aff17-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff><aff id="aff18-2055217317727296">Pharmacy Department, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Muldowney</surname><given-names>Ciaran</given-names></name></contrib><aff id="aff19-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff><aff id="aff20-2055217317727296">Pharmacy Department, St Vincent's University Hospital, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Cassidy</surname><given-names>Lorraine</given-names></name></contrib><aff id="aff21-2055217317727296">Department of Neuro-ophthamology, <institution-wrap><institution-id institution-id-type="Ringgold">58010</institution-id><institution content-type="university">Royal Victoria Eye and Ear Hospital</institution></institution-wrap>, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Walsh</surname><given-names>Cathal</given-names></name></contrib><aff id="aff22-2055217317727296">Department of Statistics, University of Limerick, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>O&#x02019;Rourke</surname><given-names>Killian</given-names></name></contrib><aff id="aff23-2055217317727296">Department of Neurology, <institution-wrap><institution-id institution-id-type="Ringgold">8881</institution-id><institution content-type="university">Mater Misericordiae University Hospital</institution></institution-wrap>, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Tubridy</surname><given-names>Niall</given-names></name></contrib><aff id="aff24-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff><aff id="aff25-2055217317727296">School of Medicine, University College Dublin, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>McGuigan</surname><given-names>Chris</given-names></name></contrib><aff id="aff26-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff><aff id="aff27-2055217317727296">School of Medicine, University College Dublin, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fletcher</surname><given-names>Jean M</given-names></name></contrib><aff id="aff28-2055217317727296">School of Biochemistry and Immunology, Trinity College Dublin, Ireland</aff><aff id="aff29-2055217317727296">School of Medicine, Trinity College Dublin, Ireland</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hutchinson</surname><given-names>Michael</given-names></name></contrib><aff id="aff30-2055217317727296">Department of Neurology, St Vincent's University Hospital, Ireland</aff><aff id="aff31-2055217317727296">School of Medicine, University College Dublin, Ireland</aff></contrib-group><author-notes><fn fn-type="equal" id="fn1-2055217317727296"><label>*</label><p>Joint first authorship.</p></fn><corresp id="corresp1-2055217317727296">Department of Neurology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Email: <email>kazzoc@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><season>Jul-Sep</season><year>2017</year></pub-date><volume>3</volume><issue>3</issue><elocation-id>2055217317727296</elocation-id><history><date date-type="received"><day>23</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder content-type="society">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec><title>Background</title><p>Lowserum vitamin D levels are associated with susceptibility to, and severity of, multiple sclerosis. High dose vitamin D has been proposed as a potential immunomodulator in multiple sclerosis.</p></sec><sec><title>Objectives</title><p>We performed a single centre, investigator-led, exploratory, double-blind, randomised, placebo controlled, trial of vitamin D<sub>3</sub> in clinically isolated syndrome and healthy control participants to assess its immunological effects. Secondary end-points included clinical and magnetic resonance imaging outcomes and safety.</p></sec><sec><title>Methods</title><p>Clinically isolated syndrome patients and healthy control participants were randomised to: placebo, 5000&#x02009;IU or 10,000&#x02009;IU vitamin D<sub>3</sub>/day (Vigantol oil). Study duration was 24 weeks.</p></sec><sec><title>Results</title><p>The trial did not meet its primary end point, with no difference in the frequency of pro-inflammatory CD4<sup>+</sup> T cells (interleukin (IL)-17<sup>+</sup>/interferon (IFN)-&#x003b3;<sup>+</sup>) seen. A higher level of disease freedom (67% versus 50%) was seen in those with serum 1,25 (OH) vitamin D levels&#x0003e;100&#x02009;nmol/l but this did not reach significance. High dose vitamin D<sub>3</sub> was well tolerated with no safety signal.</p></sec><sec><title>Conclusions</title><p>High dose vitamin D<sub>3</sub> over 24 weeks was well tolerated but without immunological, magnetic resonance imaging or clinical evidence of benefit. The hypothesised therapeutic effects in clinically isolated syndrome or multiple sclerosis patients may require longer periods of administration or may only be seen in patients treated with vitamin D<sub>3</sub> as an adjunct to established disease modifying therapies.</p></sec></abstract><kwd-group><kwd>Multiple sclerosis</kwd><kwd>clinically isolated syndrome</kwd><kwd>vitamin D</kwd><kwd>randomised controlled trial</kwd><kwd>immunology</kwd><kwd>cholecalciferol</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>July-September 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-2055217317727296"><title>Introduction</title><p>Multiple sclerosis (MS) is a relapsing inflammatory disorder affecting the central nervous system causing demyelination, axonal and neuronal injury resulting in cerebral and spinal atrophy. Its pathogenesis is not fully understood but involves a complex interplay between genetic and environmental factors.<sup><xref rid="bibr1-2055217317727296" ref-type="bibr">1</xref></sup> There is a well recognised geographical distribution of MS with increased incidence and prevalence associated with latitude from the equator.<sup><xref rid="bibr2-2055217317727296" ref-type="bibr">2</xref></sup> The association of both MS susceptibility and disease activity with low serum vitamin D levels has emerged from a number of studies showing increased prevalence with lower levels of ultraviolet (UV) radiation<sup><xref rid="bibr3-2055217317727296" ref-type="bibr">3</xref>,<xref rid="bibr4-2055217317727296" ref-type="bibr">4</xref></sup>, a higher risk of MS in offspring of women who are deficient in vitamin D<sup><xref rid="bibr5-2055217317727296" ref-type="bibr">5</xref>,<xref rid="bibr6-2055217317727296" ref-type="bibr">6</xref></sup> which is further supported by month of birth studies;<sup><xref rid="bibr7-2055217317727296" ref-type="bibr">7</xref></sup> also, higher serum levels of vitamin D are associated with lower risk of relapse<sup><xref rid="bibr8-2055217317727296" ref-type="bibr">8</xref>,<xref rid="bibr9-2055217317727296" ref-type="bibr">9</xref></sup> and the number of new lesions on magnetic resonance imaging (MRI) scanning.<sup><xref rid="bibr10-2055217317727296" ref-type="bibr">10</xref></sup></p><p>Vitamin D has been shown to modulate both the innate and adaptive immune systems.<sup><xref rid="bibr11-2055217317727296" ref-type="bibr">11</xref></sup> The active metabolite, 1,25 (OH) vitamin D (25(OH)D), mediates its effects through the intracellular vitamin D receptor (VDR),<sup><xref rid="bibr12-2055217317727296" ref-type="bibr">12</xref></sup> which is present in monocytes, dendritic cells, B-cells and CD4<sup>+</sup> T cells.<sup><xref rid="bibr11-2055217317727296" ref-type="bibr">11</xref>,<xref rid="bibr13-2055217317727296" ref-type="bibr">13</xref></sup> Activation of VDR alters transcription, proliferation and differentiation of immune cells<sup><xref rid="bibr12-2055217317727296" ref-type="bibr">12</xref></sup> and both indirectly modulates immune response by reducing the activation of pro-inflammatory T cells by antigen presenting cells<sup><xref rid="bibr14-2055217317727296" ref-type="bibr">14</xref></sup> and directly inhibiting T cell and B cell proliferation.<sup><xref rid="bibr11-2055217317727296" ref-type="bibr">11</xref>,<xref rid="bibr15-2055217317727296" ref-type="bibr">15</xref></sup> This results in a Th2 cell driven anti-inflammatory state.<sup><xref rid="bibr13-2055217317727296" ref-type="bibr">13</xref>,<xref rid="bibr15-2055217317727296" ref-type="bibr">15</xref>,<xref rid="bibr16-2055217317727296" ref-type="bibr">16</xref></sup> The diverse effects seen within the immune system in response to vitamin D supplementation may explain the conflicting results from the small number of human studies carried out to date.<sup><xref rid="bibr17-2055217317727296" ref-type="bibr">17</xref><xref rid="bibr18-2055217317727296" ref-type="bibr"/><xref rid="bibr19-2055217317727296" ref-type="bibr"/><xref rid="bibr20-2055217317727296" ref-type="bibr"/><xref rid="bibr21-2055217317727296" ref-type="bibr"/><xref rid="bibr22-2055217317727296" ref-type="bibr"/>&#x02013;<xref rid="bibr23-2055217317727296" ref-type="bibr">23</xref></sup></p><p>Clinically isolated syndrome (CIS) refers to patients presenting with a first-ever symptom consistent with demyelination and without evidence of dissemination in time.<sup><xref rid="bibr24-2055217317727296" ref-type="bibr">24</xref></sup> CIS patients have a well-established natural history, with an increased risk of MS associated with the number of asymptomatic MRI T2 lesions at presentation.<sup><xref rid="bibr25-2055217317727296" ref-type="bibr">25</xref></sup> In many countries, including Ireland, a conservative approach of &#x02018;watchful waiting&#x02019;, rather than the immediate introduction of disease-modifying therapy, is taken. Vitamin D deficiency is common in Ireland,<sup><xref rid="bibr26-2055217317727296" ref-type="bibr">26</xref></sup> as in many northern European countries and may contribute to both disease susceptibility and disease severity. We hypothesised that treatment of CIS patients with vitamin D<sub>3</sub> supplementation might reduce the risk of progression to either clinically- or MRI-confirmed MS. Therefore we carried out a randomised, double-blind, placebo-controlled trial of vitamin D<sub>3</sub> supplementation in CIS patients to assess the immunological and therapeutic effects, if any, of vitamin D<sub>3</sub> supplementation in these patients. Healthy control participants were also prospectively recruited to investigate if the immunological responses to vitamin D<sub>3</sub> supplementation differed between control participants and those with CIS. We also wanted to determine whether high dose vitamin D<sub>3</sub> is a safe and effective therapy for patients with CIS.</p></sec><sec id="sec2-2055217317727296"><title>Participants and methods</title><sec id="sec3-2055217317727296"><title>Study participants</title><sec id="sec4-2055217317727296"><title>Inclusion criteria</title><p>
<list list-type="order" id="list1-2055217317727296"><list-item><p>CIS patients aged between 18&#x02013;55 years with symptom onset within three months of screening, having two or more asymptomatic T2 lesions on brain MRI consistent with demyelination, not treated with steroids within 30 days of screening and not on any other disease-modifying therapy.</p></list-item><list-item><p>Healthy control participants (HCPs) were aged between 20&#x02013;40 years with a female: male ratio of 2:1, broadly in line with the gender ratio of CIS.</p></list-item></list>
</p></sec><sec id="sec5-2055217317727296"><title>Exclusion criteria</title><p>
<list list-type="order" id="list2-2055217317727296"><list-item><p>Exclusion criteria in both CIS patients and HCPs were: no history or evidence of hypercalcaemia, renal impairment, vitamin D intolerance, parathyroid dysfunction, sarcoidosis, pregnancy or refusal to use contraception, prior or current treatment with thiazide diuretics or vitamin D supplementation of greater than 1000&#x02009;IU/day.</p></list-item><list-item><p>Exclusion criteria in patients with CIS were: (a) patients whose symptoms might be explained by a diagnosis other than MS; (b) patients with occurrence of an exacerbation less than six weeks prior to entry to the study; (c) previous treatment with any immunomodulating therapy in the last three months, steroids in the last four weeks or any previous treatment with mitoxantrone or other immunosuppressant.</p></list-item></list>
</p></sec></sec><sec id="sec6-2055217317727296"><title>Trial design</title><p>This was a single-centre, investigator-led, exploratory, double-blind, dose-ranging, randomised, placebo-controlled trial. A full detailed trial protocol has been previously published.<sup><xref rid="bibr27-2055217317727296" ref-type="bibr">27</xref></sup> Detailed procedures carried out at each study visit are available in the Supplementary Material, Methods section. Participants were enrolled from November 2012 and last study visit was June 2015. Both HCPs and CIS patients were recruited over the same time period and studied in parallel. Both the HCPs and CIS patients were randomised to one of three interventions: placebo oil, 5000&#x02009;IU and 10,000&#x02009;IU vitamin D<sub>3</sub> per day. The vitamin D<sub>3</sub> was in the form of Vigantol Oil, supplied by Merck KgaA (Darmstadt, Germany). Both placebo and the active product were identical in appearance.</p></sec><sec id="sec7-2055217317727296"><title>Endpoints</title><p>The primary endpoint was the effect of oral vitamin D<sub>3</sub> at 5000&#x02009;IU and 10,000&#x02009;IU per day compared to placebo on the frequency of CD4<sup>+</sup> T cell subsets (interleukin (IL)-17<sup>+</sup>CD4<sup>+</sup> T cells and interferon (IFN)-&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells) and cytokine (IL-17, IL-10 and IFN-&#x003b3;) responses in peripheral blood mononuclear cells (PBMCs) in patients with CIS and HCPs at 16 and 24 weeks compared to baseline.</p><p>Secondary endpoints included determining if, in CIS patients, there was a difference in the response to 5000&#x02009;IU and 10,000&#x02009;IU vitamin D<sub>3</sub>, compared to placebo in:
<list list-type="order" id="list3-2055217317727296"><list-item><p>Radiological activity as measured by the number of new or enlarging T2 lesions and gadolinium-enhancing lesions on brain MRI at 24 weeks compared to baseline.</p></list-item><list-item><p>Clinical activity as measured by the annualised relapse rate (ARR), percentage of patients relapse-free and time to first relapse.</p></list-item><list-item><p>Disease freedom as measured by the percentage of patients with no evidence of either radiological or clinical activity.</p></list-item></list></p><p>We also wished to determine the dose response and safety and tolerability of high dose vitamin D<sub>3</sub> supplementation in both CIS patients and HCPs.</p></sec><sec id="sec8-2055217317727296"><title>Study procedures</title><p>Study visits were performed at baseline and then at four-weekly intervals over a 24-week period. A follow-up visit was arranged at week 28&#x02013;30. At each visit, changes in medical and neurological history or medications were recorded. All patients had a full physical examination and CIS participants has their Expanded Disability Status Scale (EDSS) score recorded and were assessed for any evidence of a relapse. Treatment adherence, as measured by the volume of study drug returned at each visit, and any adverse events were also noted.</p></sec><sec id="sec9-2055217317727296"><title>Vitamin D and parathyroid hormone</title><p>Plasma parathyroid hormone (PTH) levels were measured at baseline, week 4, 8, 16, 24 and 28&#x02013;30 using the Roche intact PTH assay on the Cobas E411 Electrochemiluminescent Immunoassay Analyser (Roche Diagnostics GmbH, Mannheim, Germany). Serum 25(OH)D levels were measured by liquid chromatography mass spectrometry (LC-MS/MS) using a Waters Acquity ultra performance liquid chromatography (UPLC) coupled to a triple quadrupole mass (TQD) (Waters Corp., Milford, USA) with a semi-automated solid phase extraction (SPE) preparation of patient serum samples (Tecan Freedom Evo 100, Switzerland). A more detailed description is available in the Supplementary Material, Methods section.</p><p>Biochemistry, including urea and electrolytes, serum creatinine, liver function and serum calcium levels adjusted for albumin level, was measured at each study visit.</p></sec><sec id="sec10-2055217317727296"><title>Immunological outcome measures</title><p>PBMCs were isolated and cryopreserved, and immunological analyses were performed upon completion of the study. PBMCs from all time-points were thawed in batches, labelled with cell tracker dye CellTrace Violet (CTV) (Invivogen), and cultured at 2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/ml in a 48-well plate (0.5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells in total) in complete Roswell Park memorial institute (RPMI) medium and were left unstimulated or stimulated with the following: 1&#x02009;&#x000b5;g/ml anti-CD3 (eBioscience), 0.5&#x02009;&#x000d7;&#x02009;10<sup>6</sup> irradiated allogeneic PBMCs, 1&#x02009;&#x000b5;g/ml each of purified protein derivative (PPD; Serum Staten Institute) and tetanus toxoid (TT) as recall antigens, and 0.625&#x02009;&#x000b5;g/ml/0.375&#x02009;nM each of myelin oligodendrocyte protein (MOG) and myelin basic protein (MBP) PepTivator overlapping peptides (Miltenyi Biotech). In parallel with each batch of samples the same standardised PBMC sample was included in order to monitor reproducibility between batches. After three days for anti-CD3, or seven days for antigen-specific stimuli, cell culture supernatants were removed and the concentrations of IFN-&#x003b3;, IL-17 and IL-10 were analysed by enzyme-linked immunosorbent assay (ELISA) (eBioscience). In addition, the cells were restimulated with 50&#x02009;ng/ml phorbol myristate acetate (PMA), 500&#x02009;ng/ml ionomycin and 5&#x02009;&#x000b5;g/ml of Brefeldin A for five hours (all Sigma), followed by staining for cell-surface CD3 and CD8 and intracellular IL-17 and IFN-&#x003b3; (eBioscience). Cells were analysed by flow cytometry using a BD LSRFortessa Cell Analyser (BD Biosciences) and FlowJo software. T cell proliferation was analysed by CTV dilution.</p></sec><sec id="sec11-2055217317727296"><title>MRI acquisition</title><p>Brain MRI was acquired at baseline and 24 weeks with contiguous axial 3&#x02009;mm thick slices. Sequences included: axial and coronal T1-weighted spin echo (pre and post gadolinium), axial and sagittal PD/T2-weighted and axial fast fluid-attenuated inversion recovery (FLAIR). Baseline and 24-week scans were reviewed by two radiologists who were blinded to treatment group. MRI assessment included: (a) number of gadolinium-enhancing lesions; (b) number of new and enlarging T2 lesions; (c) total number of new lesions&#x02009;=&#x02009;number of gadolinium-enhancing lesions plus number of new and enlarging T2 lesions.</p></sec><sec id="sec12-2055217317727296"><title>Statistical methods</title><p>Power calculations were based on a pilot study<sup><xref rid="bibr28-2055217317727296" ref-type="bibr">28</xref></sup> using &#x003b1; of 5% and &#x003b2; of 80%. A detailed description is available in the Supplementary Material, Methods section. All serum 25(OH)D levels were adjusted for season<sup><xref rid="bibr29-2055217317727296" ref-type="bibr">29</xref></sup> and these values were used in all further analysis. All data was inspected for normality using histograms, skewness and kurtosis and normality tests (Kolmogorov-Smirnov and Shapiro-Wilk). Values displayed include mean and standard deviation (SD) or median and interquartile range where appropriate. Within group differences between baseline and follow-up were assessed using the Wilcoxon Rank test as outlined in the protocol. Log<sub>10</sub> ratio of week 16/baseline and week 24/baseline was calculated and adjusted for baseline measurements (including vitamin D level) and between group differences were compared using the <italic>t</italic>-test or Mann Whitney U test where indicated. All analysis was carried out in SPSS version 20.</p></sec><sec id="sec13-2055217317727296"><title>Ethical approval</title><p>Ethical approval was granted by St Vincent&#x02019;s University Hospital Ethics and Medical Research Committee and the study was approved by the Health Products Regulatory Authority (HPRA). The trial was registered with ClinicalTrials.gov (NCT01728922) and the European Union Clinical Trials Register (EudraCT: 2012-000635-68).</p></sec></sec><sec sec-type="results" id="sec14-2055217317727296"><title>Results</title><sec id="sec15-2055217317727296"><title>Study participants</title><p>Recruitment to the study is outlined in <xref ref-type="fig" rid="fig1-2055217317727296">Figure 1</xref>. Baseline characteristics of subjects in each treatment arm are outlined in <xref ref-type="table" rid="table1-2055217317727296">Table 1</xref>. All participants were Caucasian. No significant differences were seen between each of the three treatment arms in either CIS patients or HCPs. Mean baseline EDSS was 0.9 (SD: 1), 0.9 (SD: 1.2) and 0.4 (SD: 0.5) in each of the 10,000&#x02009;IU, 5000&#x02009;IU and placebo groups respectively. No patients were on disease modifying treatment as per protocol.
<table-wrap id="table1-2055217317727296" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics of both clinically isolated syndrome (CIS) patients and healthy control participants (HCPs).</p></caption><alternatives><graphic specific-use="table1-2055217317727296" xlink:href="10.1177_2055217317727296-table1"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th colspan="3" rowspan="1">Clinically isolated syndrome (<italic>n</italic>&#x02009;=&#x02009;29)<hr/></th><th colspan="3" rowspan="1">Healthy control participants (<italic>n</italic>&#x02009;=&#x02009;38)<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">10,000&#x02009;IU (<italic>n</italic>&#x02009;=&#x02009;12)</th><th rowspan="1" colspan="1">5000&#x02009;IU (<italic>n</italic>&#x02009;=&#x02009;10)</th><th rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x02009;=&#x02009;7)</th><th rowspan="1" colspan="1">10,000&#x02009;IU (<italic>n</italic>&#x02009;=&#x02009;13)</th><th rowspan="1" colspan="1">5000&#x02009;IU (<italic>n</italic>&#x02009;=&#x02009;13)</th><th rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x02009;=&#x02009;12)</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">Female <italic>n</italic> (%)</td><td rowspan="1" colspan="1"> 8 (67)</td><td rowspan="1" colspan="1"> 5 (50)</td><td rowspan="1" colspan="1"> 6 (86)</td><td rowspan="1" colspan="1"> 6 (46)</td><td rowspan="1" colspan="1"> 10 (77)</td><td rowspan="1" colspan="1"> 10 (83)</td></tr><tr><td rowspan="1" colspan="1">Age (years) mean (SD)</td><td rowspan="1" colspan="1"> 37.2 (8.7)</td><td rowspan="1" colspan="1"> 32.7 (4.6)</td><td rowspan="1" colspan="1"> 34.3 (10.6)</td><td rowspan="1" colspan="1"> 30.5 (5.1)</td><td rowspan="1" colspan="1"> 30.3 (3.7)</td><td rowspan="1" colspan="1"> 29.1 (4.7)</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>) mean (SD)</td><td rowspan="1" colspan="1"> 30.6 (5.6)</td><td rowspan="1" colspan="1"> 26.3 (3.4)</td><td rowspan="1" colspan="1"> 26.7 (4.2)</td><td rowspan="1" colspan="1"> 25.4 (3.2)</td><td rowspan="1" colspan="1"> 23.5 (3.3)</td><td rowspan="1" colspan="1"> 27.6 (4.3)</td></tr><tr><td rowspan="1" colspan="1">Ever smoked <italic>n</italic> (%)</td><td rowspan="1" colspan="1"> 7 (58)</td><td rowspan="1" colspan="1"> 5 (50)</td><td rowspan="1" colspan="1"> 3 (43)</td><td rowspan="1" colspan="1"> 2 (15)</td><td rowspan="1" colspan="1"> 3 (23)</td><td rowspan="1" colspan="1"> 4 (33)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-2055217317727296"><p>BMI: body mass index; SD: standard deviation.</p></fn></table-wrap-foot></table-wrap>
<fig id="fig1-2055217317727296" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Schematic diagram outlining recruitment to the study, randomization and final analysis.</p></caption><graphic xlink:href="10.1177_2055217317727296-fig1"/></fig></p></sec><sec id="sec16-2055217317727296"><title>Serum 25(OH)D, PTH and calcium levels</title><p>There was no difference in mean baseline serum 25(OH)D levels between CIS patients and HCP (53 vs 52&#x02009;nmol/l, <italic>p</italic>&#x02009;=&#x02009;0.8). For the CIS group, in the placebo, 5000&#x02009;IU and 10,000&#x02009;IU treatment arms, mean changes in serum 25(OH)D levels from baseline to week 16 were 7&#x02009;nmol/l (SD: 26), 81&#x02009;nmol/l (SD: 63) and 121&#x02009;nmol/l (SD: 35); from baseline to week 24, mean changes were 18&#x02009;nmol/l (SD: 34), 76&#x02009;nmol/l (SD: 57) and 115&#x02009;nmol/l (SD: 51) respectively. For the HCP group, in the placebo, 5000&#x02009;IU and 10,000&#x02009;IU treatment arms, mean changes in serum 25(OH)D levels from baseline to week 16 were 4&#x02009;nmol/(SD: 12), 83&#x02009;nmol/l (SD: 27) and 152&#x02009;nmol/l (SD: 71) and from baseline to week 24 were 2&#x02009;nmol/l (SD: 14), 92&#x02009;nmol/l (SD: 35) and 136&#x02009;nmol/l (SD: 71) respectively (<xref ref-type="fig" rid="fig2-2055217317727296">Figure 2</xref>).
<fig id="fig2-2055217317727296" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Graph showing median (boxes: 25&#x02013;75% interquartile range and error bars: minimum&#x02013;maximum) seasonally adjusted serum 1,25 (OH) vitamin D (25(OH)D) levels (nmol/l) achieved in each of the treatment arms at baseline, week 16 and week 24. CIS: clinically isolated syndrome; HCP: healthy control participant.</p></caption><graphic xlink:href="10.1177_2055217317727296-fig2"/></fig></p><p>These changes were significant in both the 10,000&#x02009;IU and 5000&#x02009;IU treatment arms when compared to placebo in both CIS patients and HCPs (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). Adjusting for baseline serum 25(OH)D levels, no significant differences in serum 25(OH)D levels achieved were seen between CIS patients and HCPs in any treatment arm. No cases of hypercalcaemia (reference range: 2.2&#x02013;2.6&#x02009;mmol/l) were recorded in any participant. Mean plasma PTH levels were lower in both treatment arms compared to placebo at all time-points in both CIS patients and HCPs.</p></sec><sec id="sec17-2055217317727296"><title>Immunological responses to supplementation</title><p>The primary outcome of the study was the change in T cell subsets (IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup>/IL-17<sup>+</sup>CD4<sup>+</sup> T cells) in response to supplementation. No significant reduction in either IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup>/IL-17<sup>+</sup>CD4<sup>+</sup> T cells was seen in any treatment arm at any time-point regardless of method of stimulation (polyclonal or antigen specific with MOG/MBP peptides, recall antigens (PPD/TT) or irradiated allogeneic PBMCs). Results of polyclonal stimulation in both CIS patients and HCPs are presented in <xref ref-type="table" rid="table2-2055217317727296">Table 2</xref> and antigen-specific stimulation in CIS patients in <xref ref-type="table" rid="table3-2055217317727296">Table 3</xref>. Similarly no significant differences were observed in concentrations as measured by ELISA of IL-10, IL-17 and IFN-&#x003b3; produced followed stimulation of PBMCs in any treatment arm (Supplementary Material, Table 1). Stratifying the groups based on the increase in serum 25(OH)D level (&#x0003c;50&#x02009;nmol/L/&#x02265;50&#x02009;nmol/L) seen at each time-point showed a trend towards lower IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells in both CIS patients and HCPs with significance seen at week 16 in CIS (<italic>p</italic>&#x02009;=&#x02009;0.01) and week 16 (<italic>p</italic>&#x02009;=&#x02009;0.03) and week 24 (<italic>p</italic>&#x02009;=&#x02009;0.02) in HCP (<xref ref-type="fig" rid="fig3-2055217317727296">Figure 3</xref>). All values were adjusted for baseline value but not for multiple comparisons.
<table-wrap id="table3-2055217317727296" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Paired comparison between baseline and week 16 and baseline and week 24 of percentage interferon (IFN)-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells and interleukin (IL)-17<sup>+</sup>CD4<sup>+</sup> proliferating T cells from antigen-specific stimulated peripheral blood mononuclear cells (PBMCs) from clinically isolated syndrome (CIS) patients. Values are displayed as median and interquartile range.</p></caption><alternatives><graphic specific-use="table3-2055217317727296" xlink:href="10.1177_2055217317727296-table3"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th colspan="6" rowspan="1">MOG/MBP stimulation<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Week 0</th><th rowspan="1" colspan="1">Week 16</th><th rowspan="1" colspan="1"><italic>p</italic>-Value</th><th rowspan="1" colspan="1">Week 0</th><th rowspan="1" colspan="1">Week 24</th><th rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">0.7 (0.1&#x02013;1.1)</td><td rowspan="1" colspan="1">0.55 (0.2&#x02013;1.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.45</td><td rowspan="1" colspan="1">0.7 (0.1&#x02013;1.1)</td><td rowspan="1" colspan="1">1.1 (0.5&#x02013;1.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.04<sup><xref ref-type="table-fn" rid="table-fn3-2055217317727296">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">0.95 (0.3&#x02013;4.4)</td><td rowspan="1" colspan="1">1.13 (0.7&#x02013;1.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.39</td><td rowspan="1" colspan="1">0.95 (0.3&#x02013;4.4)</td><td rowspan="1" colspan="1">1.3 (0.7&#x02013;3.0)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.29</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.54 (0.2&#x02013;1.4)</td><td rowspan="1" colspan="1">0.6 (0.2&#x02013;1.1)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.23</td><td rowspan="1" colspan="1">0.54 (0.2&#x02013;1.4)</td><td rowspan="1" colspan="1">0.38 (0.2&#x02013;0.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.17</td></tr><tr><td rowspan="1" colspan="1">IL-17<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">0.42 (0.1&#x02013;1.0)</td><td rowspan="1" colspan="1">0.21 (0.1&#x02013;0.7)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.24</td><td rowspan="1" colspan="1">0.42 (0.1&#x02013;1.0)</td><td rowspan="1" colspan="1">0.36 (0.1&#x02013;0.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.37</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">0.06 (0.03&#x02013;0.2)</td><td rowspan="1" colspan="1">0.07 (0.03&#x02013;0.3)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.4</td><td rowspan="1" colspan="1">0.06 (0.03&#x02013;0.2)</td><td rowspan="1" colspan="1">0.29 (0.05&#x02013;0.4)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.5</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.1 (0.07&#x02013;0.3)</td><td rowspan="1" colspan="1">0.37 (0.05&#x02013;0.4)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.23</td><td rowspan="1" colspan="1">0.1 (0.07&#x02013;0.3)</td><td rowspan="1" colspan="1">0.14 (0.1&#x02013;0.7)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.9</td></tr><tr><td rowspan="1" colspan="1"/><td colspan="6" rowspan="1"><hr/>PPD stimulation</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><hr/>Week 0</td><td rowspan="1" colspan="1"><hr/>Week 16</td><td rowspan="1" colspan="1"><hr/><italic>p</italic>-Value</td><td rowspan="1" colspan="1"><hr/>Week 0</td><td rowspan="1" colspan="1"><hr/>Week 24</td><td rowspan="1" colspan="1"><hr/><italic>p</italic>-Value</td></tr><tr><td rowspan="1" colspan="1">IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">0.45 (0.2&#x02013;2.1)</td><td rowspan="1" colspan="1">0.87 (0.2&#x02013;2.6)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.44</td><td rowspan="1" colspan="1">0.45 (0.2&#x02013;2.1)</td><td rowspan="1" colspan="1">1.2 (0.3&#x02013;3.3)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.04<sup><xref ref-type="table-fn" rid="table-fn3-2055217317727296">a</xref></sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">0.61 (0.4&#x02013;1.7)</td><td rowspan="1" colspan="1">1.21 (0.6&#x02013;2.1)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.29</td><td rowspan="1" colspan="1">0.61 (0.4&#x02013;1.7)</td><td rowspan="1" colspan="1">1.3 (0.6&#x02013;2.6)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.61</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.69 (0.05&#x02013;1.6)</td><td rowspan="1" colspan="1">1.19 (0.4&#x02013;1.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.04<sup><xref ref-type="table-fn" rid="table-fn3-2055217317727296">a</xref></sup></td><td rowspan="1" colspan="1">0.69 (0.05&#x02013;1.6)</td><td rowspan="1" colspan="1">0.37 (0.1&#x02013;2.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.46</td></tr><tr><td rowspan="1" colspan="1">IL-17<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">0.27 (0.7&#x02013;3.0)</td><td rowspan="1" colspan="1">0.27 (0.1&#x02013;1.6)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.7</td><td rowspan="1" colspan="1">0.27 (0.7&#x02013;3.0)</td><td rowspan="1" colspan="1">0.38 (0.1&#x02013;2.0)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.7</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">0.13 (0.01&#x02013;0.4)</td><td rowspan="1" colspan="1">0.12 (0.04&#x02013;0.3)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.88</td><td rowspan="1" colspan="1">0.13 (0.01&#x02013;0.4)</td><td rowspan="1" colspan="1">0.22 (0.04&#x02013;0.4)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.8</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.49 (0.2&#x02013;1.4)</td><td rowspan="1" colspan="1">0.56 (0.3&#x02013;0.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.47</td><td rowspan="1" colspan="1">0.49 (0.2&#x02013;1.4)</td><td rowspan="1" colspan="1">0.29 (0.1&#x02013;1.1)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.23</td></tr><tr><td rowspan="1" colspan="1"/><td colspan="6" rowspan="1"><hr/>Allogeneic stimulation</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><hr/>Week 0</td><td rowspan="1" colspan="1"><hr/>Week 16</td><td rowspan="1" colspan="1"><hr/><italic>p</italic>-Value</td><td rowspan="1" colspan="1"><hr/>Week 0</td><td rowspan="1" colspan="1"><hr/>Week 24</td><td rowspan="1" colspan="1"><hr/><italic>p</italic>-Value</td></tr><tr><td rowspan="1" colspan="1">IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">1.24 (0.7&#x02013;2.7)</td><td rowspan="1" colspan="1">1.1 (0.9&#x02013;3.1)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.89</td><td rowspan="1" colspan="1">1.24 (0.7&#x02013;2.7)</td><td rowspan="1" colspan="1">1.74 (0.6&#x02013;2.9)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.95</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">4.5 (1.3 (1.3&#x02013;7.7)</td><td rowspan="1" colspan="1">1.5 (0.9&#x02013;2.7)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.02<sup>b</sup></td><td rowspan="1" colspan="1">4.5 (1.3&#x02013;7.7)</td><td rowspan="1" colspan="1">1.75 (0.8&#x02013;2.8)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.008<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.89 (0.3&#x02013;1.3)</td><td rowspan="1" colspan="1">1.1 (0.6&#x02013;1.7)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.69</td><td rowspan="1" colspan="1">0.89 (0.3&#x02013;1.3)</td><td rowspan="1" colspan="1">1.6 (0.1&#x02013;1.7)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.35</td></tr><tr><td rowspan="1" colspan="1">IL-17<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">1.15 (0.3&#x02013;1.8)</td><td rowspan="1" colspan="1">0.73 (0.2&#x02013;1.6)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.31</td><td rowspan="1" colspan="1">1.15 (0.3&#x02013;1.8)</td><td rowspan="1" colspan="1">0.14 (0.1&#x02013;1.4)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.07</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">0.52 (0.2&#x02013;1.2)</td><td rowspan="1" colspan="1">0.33 (0.2&#x02013;0.5)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.14</td><td rowspan="1" colspan="1">0.52 (0.2&#x02013;1.2)</td><td rowspan="1" colspan="1">0.43 (0.1&#x02013;1.8)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.77</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.2 (0.1&#x02013;0.6)</td><td rowspan="1" colspan="1">0.51 (0.3&#x02013;0.7)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.27</td><td rowspan="1" colspan="1">0.2 (0.1&#x02013;0.6)</td><td rowspan="1" colspan="1">0.56 (0.3&#x02013;0.8)</td><td rowspan="1" colspan="1"><italic>p</italic>&#x02009;=&#x02009;0.35</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-2055217317727296"><label>a</label><p>A significant increase in IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells at that time point; <sup>b</sup>a significant reduction in IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells at that time point.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="table2-2055217317727296" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Paired comparison between baseline and week 16 and baseline and week 24 of percentage interferon (IFN)-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells and interleukin (IL)-17<sup>+</sup>CD4<sup>+</sup> proliferating T cells amongst each treatment arm in both clinically isolated syndrome (CIS) and healthy control participants (HCPs). Values are displayed as median and interquartile range.</p></caption><alternatives><graphic specific-use="table2-2055217317727296" xlink:href="10.1177_2055217317727296-table2"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th colspan="6" rowspan="1">CIS<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Week 0</th><th rowspan="1" colspan="1">Week 16</th><th rowspan="1" colspan="1"><italic>p</italic>-Value</th><th rowspan="1" colspan="1">Week 0</th><th rowspan="1" colspan="1">Week 24</th><th rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">IFN-&#x003b3;<sup>+</sup>CD4+ proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">7.3 (1.2&#x02013;10.3)</td><td rowspan="1" colspan="1">7 (2.3&#x02013;8.6)</td><td rowspan="1" colspan="1">0.646</td><td rowspan="1" colspan="1">7.3 (1.2&#x02013;10.3)</td><td rowspan="1" colspan="1">5.1 (2.5&#x02013;7.6)</td><td rowspan="1" colspan="1">0.169</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5,000 IU</td><td rowspan="1" colspan="1">5.8 (3.3&#x02013;6.8)</td><td rowspan="1" colspan="1">4.9 (3.6&#x02013;10.2)</td><td rowspan="1" colspan="1">0.594</td><td rowspan="1" colspan="1">5.8 (3.3&#x02013;6.8)</td><td rowspan="1" colspan="1">6.4 (4.7&#x02013;8.6)</td><td rowspan="1" colspan="1">0.674</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">4.7 (4.3&#x02013;5.6)</td><td rowspan="1" colspan="1">7 (4.3&#x02013;9)</td><td rowspan="1" colspan="1">0.043</td><td rowspan="1" colspan="1">4.7 (4.3&#x02013;5.6)</td><td rowspan="1" colspan="1">6 (1.1&#x02013;7.3)</td><td rowspan="1" colspan="1">0.6</td></tr><tr><td rowspan="1" colspan="1">IL-17<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">0.8 (0.1&#x02013;2)</td><td rowspan="1" colspan="1">1.3 (0.6&#x02013;3.2)</td><td rowspan="1" colspan="1">0.015<sup><xref ref-type="table-fn" rid="table-fn2-2055217317727296">a</xref></sup></td><td rowspan="1" colspan="1">0.8 (0.1&#x02013;2)</td><td rowspan="1" colspan="1">0.7 (0.3&#x02013;2.9)</td><td rowspan="1" colspan="1">0.484</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">1.1 (0.6&#x02013;2.9)</td><td rowspan="1" colspan="1">1.4 (0.8&#x02013;2.9)</td><td rowspan="1" colspan="1">0.374</td><td rowspan="1" colspan="1">1.1 (0.6&#x02013;2.9)</td><td rowspan="1" colspan="1">1.7 (0.5&#x02013;2.4)</td><td rowspan="1" colspan="1">0.767</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.3 (0.2&#x02013;0.9)</td><td rowspan="1" colspan="1">0.6 (0.2&#x02013;1.9)</td><td rowspan="1" colspan="1">0.046<sup><xref ref-type="table-fn" rid="table-fn2-2055217317727296">a</xref></sup></td><td rowspan="1" colspan="1">0.3 (0.2&#x02013;0.9)</td><td rowspan="1" colspan="1">0.8 (0&#x02013;13)</td><td rowspan="1" colspan="1">0.173</td></tr><tr><td rowspan="1" colspan="1"/><td colspan="6" rowspan="1"><hr/>HCPs</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><hr/>Week 0</td><td rowspan="1" colspan="1"><hr/>Week 16</td><td rowspan="1" colspan="1"><hr/><italic>p</italic>-Value</td><td rowspan="1" colspan="1"><hr/>Week 0</td><td rowspan="1" colspan="1"><hr/>Week 24</td><td rowspan="1" colspan="1"><hr/><italic>p</italic>-Value</td></tr><tr><td rowspan="1" colspan="1">IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">9.3 (7&#x02013;12.6)</td><td rowspan="1" colspan="1">11.3 (3.3&#x02013;13.1)</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">9.3 (7&#x02013;12.6)</td><td rowspan="1" colspan="1">8.9 (4.5&#x02013;12.3)</td><td rowspan="1" colspan="1">0.29</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">8.5 (5&#x02013;10.9)</td><td rowspan="1" colspan="1">6.5 (3.1&#x02013;11.5)</td><td rowspan="1" colspan="1">0.59</td><td rowspan="1" colspan="1">8.5 (5&#x02013;10.9)</td><td rowspan="1" colspan="1">8.2 (4.8&#x02013;12.3)</td><td rowspan="1" colspan="1">0.93</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">4.9 (2.5&#x02013;7.5)</td><td rowspan="1" colspan="1">5.9 (1.4&#x02013;12.6)</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">4.9 (2.5&#x02013;7.5)</td><td rowspan="1" colspan="1">6.2 (3.8&#x02013;12.6)</td><td rowspan="1" colspan="1">0.04<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">IL-17+CD4+ proliferating T cells</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;10,000 IU</td><td rowspan="1" colspan="1">0.6 (0.4&#x02013;0.9)</td><td rowspan="1" colspan="1">0.5 (0.3&#x02013;1.2)</td><td rowspan="1" colspan="1">0.37</td><td rowspan="1" colspan="1">0.6 (0.4&#x02013;0.9)</td><td rowspan="1" colspan="1">0.7 (0.5&#x02013;1.6)</td><td rowspan="1" colspan="1">0.46</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5000 IU</td><td rowspan="1" colspan="1">1 (0.5&#x02013;1.6)</td><td rowspan="1" colspan="1">0.6 (0.3&#x02013;0.9)</td><td rowspan="1" colspan="1">0.18</td><td rowspan="1" colspan="1">1 (0.5&#x02013;1.6)</td><td rowspan="1" colspan="1">0.5 (0.3&#x02013;1.7)</td><td rowspan="1" colspan="1">0.86</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Placebo</td><td rowspan="1" colspan="1">0.8 (0.3&#x02013;1.5)</td><td rowspan="1" colspan="1">0.8 (0.3&#x02013;1.9)</td><td rowspan="1" colspan="1">0.75</td><td rowspan="1" colspan="1">0.8 (0.3&#x02013;1.5)</td><td rowspan="1" colspan="1">1.3 (0.4&#x02013;2.8)</td><td rowspan="1" colspan="1">0.64</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-2055217317727296"><label>a</label><p>A significant increase in Ll-17<sup>+</sup>CD4<sup>+</sup> T cells seen at these time-points in the 10,000&#x02009;IU and placebo groups; <sup>b</sup>a significant increase in IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> T-cells was seen at this time-points in the placebo group.</p></fn></table-wrap-foot></table-wrap>
<fig id="fig3-2055217317727296" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Comparison between change in interferon (IFN)-&#x003b3;+CD4+ proliferating T cells, and interleukin (IL)-17+CD4+ proliferating T cells between baseline and week 16 and baseline and week 24 between CIS and HCP. Values are expressed as a log10 ratio of week 16/baseline and week 24/baseline. The clinically isolated syndrome (CIS) and healthy control participant (HCP) groups have been stratified into two groups based on a change in serum 1,25 (OH) vitamin D (25(OH)D) of &#x0003c;50&#x02009;nmol/l and &#x02265;50&#x02009;nmol/l seen at each time-point.</p></caption><graphic xlink:href="10.1177_2055217317727296-fig3"/></fig></p></sec><sec id="sec18-2055217317727296"><title>MRI results</title><p>Baseline and 24-week MRI scans were available in 26 CIS patients. An incorrect or incomplete protocol was carried out in three patients. Baseline T2 lesions and changes on follow-up MRI are outlined in <xref ref-type="table" rid="table4-2055217317727296">Table 4</xref>. No significant differences were seen between the number of new lesions, or the proportion of participants with new activity on follow-up MRI, between groups, controlling for both baseline T2 and gadolinium-enhancing lesions.
<table-wrap id="table4-2055217317727296" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Baseline T2 lesions on magnetic resonance imaging (MRI) and change in follow-up scan at 24 weeks per randomised group.</p></caption><alternatives><graphic specific-use="table4-2055217317727296" xlink:href="10.1177_2055217317727296-table4"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">10,000&#x02009;IU VD (<italic>n</italic>&#x02009;=&#x02009;10)</th><th rowspan="1" colspan="1">5000&#x02009;IU VD (<italic>n</italic>&#x02009;=&#x02009;9)</th><th rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x02009;=&#x02009;7)</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">Baseline T2 lesions Mean (SD)</td><td rowspan="1" colspan="1">18 (17)</td><td rowspan="1" colspan="1">23 (11)</td><td rowspan="1" colspan="1">13 (10)</td></tr><tr><td rowspan="1" colspan="1">Baseline GD-enhancing lesions Mean (SD)</td><td rowspan="1" colspan="1">0.3 (0.7)</td><td rowspan="1" colspan="1">0.3 (0.5)</td><td rowspan="1" colspan="1">0.1 (0.4)</td></tr><tr><td rowspan="1" colspan="1">New T2 lesions Mean (SD)</td><td rowspan="1" colspan="1">0.4 (0.5)</td><td rowspan="1" colspan="1">1.4 (1.7)</td><td rowspan="1" colspan="1">0.6 (0.8)</td></tr><tr><td rowspan="1" colspan="1">New GD-enhancing lesions Mean (SD)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.1 (0.3)</td><td rowspan="1" colspan="1">0.1 (0.4)</td></tr><tr><td rowspan="1" colspan="1">Number of patients with new disease activity by MRI (%)</td><td rowspan="1" colspan="1">5 (50%)</td><td rowspan="1" colspan="1">5 (56%)</td><td rowspan="1" colspan="1">3 (43%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn4-2055217317727296"><p>GD: gadolinium; SD: standard deviation; VD: vitamin D.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec19-2055217317727296"><title>Clinical outcomes</title><p>One patient had a relapse during the course of the study. Her symptoms began one day prior to her week 24 visit. She had been allocated to the 5000&#x02009;IU vitamin D<sub>3</sub> treatment group equating to mean ARR of 0.2 in this group. No patient fulfilled standard EDSS criteria for evidence of disability progression. No significant difference in EDSS between groups was seen at any time-point.</p></sec><sec id="sec20-2055217317727296"><title>Combined clinical and radiological outcomes</title><p>Disease freedom at the end of the study as measured by percentage of participants with no evidence of MRI or clinical activity was 50% (5/10), 33% (3/9) and 57% (4/7) in the 10,000&#x02009;IU, 5000&#x02009;IU vitamin D<sub>3</sub> and placebo arms respectively. Adjusting for baseline serum 25(OH)D level and, comparing CIS patients with a serum 25(OH)D level of &#x0003c;100&#x02009;nmol/l at week 24 to those with a level &#x02265;100&#x02009;nmol/l showed a disease freedom rate of 50% (7/14) compared to 67% (8/12) (<italic>p</italic>&#x02009;=&#x02009;0.4).</p></sec><sec id="sec21-2055217317727296"><title>Safety and adverse events</title><p>There was one serious adverse event recorded during the study; a patient required hospitalisation for a lumbar discectomy. This event was reported immediately to the study sponsor and the patient withdrew from the study. However, the event was felt to be unrelated to the study drug. At the end of the study the patient was identified as being in the placebo group. A full adverse event listing is included as Supplementary Material, Tables 2 and 3.</p></sec></sec><sec sec-type="discussion" id="sec22-2055217317727296"><title>Discussion</title><p>This trial showed that vitamin D<sub>3</sub> supplementation at doses of 5000&#x02009;IU and 10,000&#x02009;IU per day is both safe and tolerable and results in significant increases in serum 25(OH)D levels in both healthy controls and CIS patients. It seems probable that serum 25(OH)D levels of greater than 100&#x02009;nmol/l are required to produce the immunological effects of vitamin D, although no consensus level exists.<sup><xref rid="bibr29-2055217317727296" ref-type="bibr">29</xref></sup> A diminished serologic response to vitamin D<sub>3</sub> supplementation has been described in MS patients compared to controls raising the possibility of different vitamin D pharmacokinetics in people with MS.<sup><xref rid="bibr30-2055217317727296" ref-type="bibr">30</xref></sup> In our study, a higher mean change in serum 25(OH)D levels was seen in the control group but this was not statistically significant. Given the relatively small sample size it was not possible to adjust for a number of confounders including age, sex and body mass index (s) across each of the treatment arms.</p><p>Analysis of the primary outcome showed no difference in the frequency of pro-inflammatory CD4<sup>+</sup> T cells (IL-17<sup>+</sup>CD4<sup>+</sup>/IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup>) between baseline and either time-point in any of the treatment arms. No difference was seen between randomisation groups or in response to varying methods of PBMC stimulation (polyclonal or antigen-specific). A significant reduction in proliferating IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> T-cells was seen in both control participants (week 16 and 24) and CIS patients (week 16) when the groups were stratified according to change in serum 25(OH)D level but these results were not adjusted for multiple comparisons and need to be interpreted with caution. Measurement of anti-inflammatory (IL-10) and pro-inflammatory (IL-17/IFN-&#x003b3;) cytokines from stimulated PBMCs by ELISA also failed to show any significant changes in response to supplementation or between randomisation groups.</p><p>The role of IL-17<sup>+</sup>CD4<sup>+</sup> T cells in MS pathogenesis has been shown in the experimental autoimmune encephalitis (EAE) model, and is also supported by high levels of IL-17 in MS plaques and cerebrospinal fluid.<sup><xref rid="bibr31-2055217317727296" ref-type="bibr">31</xref></sup> In&#x000a0;vitro studies have suggested that vitamin D significantly inhibits IL-17 production and increases IL-10 in relapsing remitting MS (RRMS) patients and controls.<sup><xref rid="bibr11-2055217317727296" ref-type="bibr">11</xref></sup> However, the results of a small number of published clinical trials exploring various immunological outcomes in response to vitamin D supplementation in MS have been conflicting and somewhat disappointing in identifying the underlying molecular immunological mechanism of vitamin D supplementation.<sup><xref rid="bibr17-2055217317727296" ref-type="bibr">17</xref><xref rid="bibr18-2055217317727296" ref-type="bibr"/><xref rid="bibr19-2055217317727296" ref-type="bibr"/><xref rid="bibr20-2055217317727296" ref-type="bibr"/><xref rid="bibr21-2055217317727296" ref-type="bibr"/><xref rid="bibr22-2055217317727296" ref-type="bibr"/>&#x02013;<xref rid="bibr23-2055217317727296" ref-type="bibr">23</xref></sup> A recent study by Sotirchos et al. showed a reduction in IL-17<sup>+</sup>CD4<sup>+</sup> T cells at week 24 in RRMS patients receiving high dose (10,400&#x02009;IU/day) vitamin D<sub>3</sub>.<sup><xref rid="bibr17-2055217317727296" ref-type="bibr">17</xref></sup> These effects were not observed in the low dose group (800&#x02009;IU/day) group and no significant change was seen in IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in either group. A Dutch sub-study of a larger clinical trial exploring high dose (up to 14,000&#x02009;IU/day) vitamin D<sub>3</sub> supplementation, as an add-on therapy to interferon&#x003b2;-1&#x02009;a in patients with RRMS, showed no difference in either IL-17<sup>+</sup>CD4<sup>+</sup> or IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells at 48 weeks follow-up.<sup><xref rid="bibr22-2055217317727296" ref-type="bibr">22</xref></sup> The investigators found a reduction in the proportion of anti-inflammatory IL-4<sup>+</sup>CD4+ T cells in the placebo group and suggested that supplementation may contribute to immune homeostasis early in the disease course.</p><p>There were methodological differences in the processing of PBMCs between these studies and our own which may have contributed towards the different percentages of IL-17<sup>+</sup>CD4<sup>+</sup> and IFN-&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells seen. The experimental design of our study was in part similar to that of Sotirchos et al. in that intracellular cytokines were measured by restimulation after an initial in&#x000a0;vitro stimulation period using cryopreserved PBMC. However, we cultured cells for three rather than five days with anti-CD3, and included additional antigen-specific stimuli. The rationale for including antigen-specific stimuli was that vitamin D<sub>3</sub> is likely to exert at least some of its anti-inflammatory effects on T cells via antigen-presenting cells, and such effects may not be apparent after polyclonal stimulation. The allogeneic stimulation would be expected to stimulate na&#x000ef;ve allo-specific T cells and would therefore reveal possible effects of vitamin D<sub>3</sub> on T cell differentiation, whereas recall antigens PPD/TT or putative MS auto-antigens MOG/MBP would restimulate antigen-specific memory T cells. In contrast, Muris et al. measured intracellular cytokine production directly ex vivo without cryopreservation or an in&#x000a0;vitro stimulation period.<sup><xref rid="bibr22-2055217317727296" ref-type="bibr">22</xref></sup> Although our study was designed to examine the effects of vitamin D<sub>3</sub> supplementation on T cell responses either directly or indirectly via the antigen presenting cell, it is possible that vitamin D<sub>3</sub> may also exert other immunologic effects that were not examined here. It has been suggested that vitamin D may have immunomodulatory effects on B cells<sup><xref rid="bibr32-2055217317727296" ref-type="bibr">32</xref></sup>, regulatory T cells<sup><xref rid="bibr33-2055217317727296" ref-type="bibr">33</xref></sup> and dendritic cells.<sup><xref rid="bibr34-2055217317727296" ref-type="bibr">34</xref></sup></p><p>The discordance between published results to date may suggest alternative hypotheses as to the observed association between vitamin D deficiency and MS. It has been argued that low serum 25(OH)D levels seen early in the disease course are a result of the disease itself and supplementation is unlikely to affect disease activity.<sup><xref rid="bibr35-2055217317727296" ref-type="bibr">35</xref></sup> Alternative environmental factors need to be considered. Ultraviolet exposure has been shown to have immunomodulating effects on skin lymphocytes<sup><xref rid="bibr36-2055217317727296" ref-type="bibr">36</xref></sup> and thus, observed vitamin D deficiency may only be a marker of lack of sunlight exposure.</p><p>Exploration of secondary endpoints showed no difference between treatment arms and placebo with regard to either radiological or clinical activity. A higher level of disease freedom (67% versus 50%) was seen in patients with serum 25(OH)D levels &#x0003e;100&#x02009;nmol/l but this was not significant. The trial was not powered to meet this endpoint and the trial duration was probably too short to detect a treatment effect of vitamin D<sub>3</sub> supplementation.</p><p>It is possible that high dose vitamin D<sub>3</sub> therapy on its own may not be sufficiently effective as an anti-inflammatory or immunomodulatory therapy in MS or CIS. There is convincing evidence, from a post-hoc analysis, that higher serum 25(OH)D levels in patients recruited into the BENEFIT and BEYOND studies had additional therapeutic effects on disease activity in patients on betaferon-1&#x02009;b.<sup><xref rid="bibr37-2055217317727296" ref-type="bibr">37</xref>,<xref rid="bibr38-2055217317727296" ref-type="bibr">38</xref></sup> Recent results from the SOLAR study of high dose vitamin D<sub>3</sub> supplementation as an add-on therapy to interferon&#x003b2;-1&#x02009;a, showed a non-significant reduction in the annualised relapse rate of 30% in the vitamin D<sub>3</sub> group at 48 weeks.<sup><xref rid="bibr39-2055217317727296" ref-type="bibr">39</xref></sup> A significant reduction in both unique new lesions and percentage change in T2 lesion volume on MRI was also seen suggesting a therapeutic benefit of supplementation. That study was hampered by difficulty with recruitment leading to a reduced trial duration. Longer follow-up and larger numbers are needed to confirm these findings. A number of trials are ongoing to address this issue.<sup><xref rid="bibr40-2055217317727296" ref-type="bibr">40</xref>,<xref rid="bibr41-2055217317727296" ref-type="bibr">41</xref></sup></p><p>The strengths of this study are that it was a double-blind randomised controlled trial and the first clinical trial of vitamin D<sub>3</sub> therapy in treatment-na&#x000ef;ve CIS patients. The HCP group allowed us to establish if immunological effects observed were unique to a CIS population. There were limitations to our study. Power calculations were based on a small pilot study<sup><xref rid="bibr28-2055217317727296" ref-type="bibr">28</xref></sup> and may have resulted in the study being underpowered. Difficulty with recruitment in the CIS group also led to smaller numbers than originally anticipated. The CIS group had a higher mean age than controls, which is a potential confounder when comparing results of some of the secondary immunologic outcomes and vitamin D pharmacokinetics. Our results were adjusted for baseline values but not for multiple comparisons, which may limit their interpretability.</p></sec><sec sec-type="conclusions" id="sec23-2055217317727296"><title>Conclusion</title><p>In conclusion, this study demonstrates that vitamin D<sub>3</sub> supplementation at doses up to 10,000&#x02009;IU daily is safe and tolerable in both HPCs and CIS patients. High dose vitamin D<sub>3</sub> supplementation did not reduce pro-inflammatory IL-17<sup>+</sup>CD4<sup>+</sup> T cells; there were possible minor effects on IFN-&#x003b3;<sup>+</sup> CD4<sup>+</sup> T cells, but no changes were observed in concentrations of IL-10, IL-17 or IFN-&#x003b3; produced by stimulated PBMCs. The potential role of vitamin D<sub>3</sub> as an immunomodulator needs to be further clarified in larger randomised controlled trials.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="MRI.pdf" orientation="portrait" id="d35e2175" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="New_Microsoft_Word_Document.pdf" orientation="portrait" id="d35e2180" position="anchor"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank all participants for their willingness for taking part in this trial.</p></ack><sec id="sec29-2055217317727296"><title>Conflicts of interest</title><p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Merck KGaA (Darmstadt, Germany) reviewed the manuscript for medical accuracy only before journal submission. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors.</p></sec><sec id="sec30-2055217317727296"><title>Funding</title><p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/ or publication of this article: The authors acknowledge the support of MS Ireland for part funding the study, Merck KgaA (Darmstadt, Germany) who provided the placebo oil and study drug (Vigantol Oil) and Biogen Idec in providing funding for the lead clinical researcher (KO&#x02019;C) through the Newman Clinical Fellowship programme.</p></sec><sec><title>Supplemental Data</title><p>Supplementary material is available for this article online.</p></sec><ref-list><title>References</title><ref id="bibr1-2055217317727296"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Coles</surname><given-names>A</given-names></name></person-group>
<article-title>Multiple sclerosis</article-title>. <source>Lancet</source>
<year>2008</year>; <volume>372</volume>: <fpage>1502</fpage>&#x02013;<lpage>1517</lpage>.<pub-id pub-id-type="pmid">18970977</pub-id></mixed-citation></ref><ref id="bibr2-2055217317727296"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>S</given-names><suffix>Jr</suffix></name><name><surname>Blizzard</surname><given-names>L</given-names></name><name><surname>Otahal</surname><given-names>P</given-names></name><etal>et al.</etal></person-group>
<article-title>Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2011</year>; <volume>82</volume>: <fpage>1132</fpage>&#x02013;<lpage>1141</lpage>.<pub-id pub-id-type="pmid">21478203</pub-id></mixed-citation></ref><ref id="bibr3-2055217317727296"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramagopalan</surname><given-names>SV</given-names></name><name><surname>Handel</surname><given-names>AE</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<article-title>Relationship of UV exposure to prevalence of multiple sclerosis in England</article-title>. <source>Neurology</source>
<year>2011</year>; <volume>76</volume>: <fpage>1410</fpage>&#x02013;<lpage>1414</lpage>.<pub-id pub-id-type="pmid">21502600</pub-id></mixed-citation></ref><ref id="bibr4-2055217317727296"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orton</surname><given-names>SM</given-names></name><name><surname>Wald</surname><given-names>L</given-names></name><name><surname>Confavreux</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<article-title>Association of UV radiation with multiple sclerosis prevalence and sex ratio in France</article-title>. <source>Neurology</source>
<year>2011</year>; <volume>76</volume>: <fpage>425</fpage>&#x02013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">21282589</pub-id></mixed-citation></ref><ref id="bibr5-2055217317727296"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzer</surname><given-names>J</given-names></name><name><surname>Hallmans</surname><given-names>G</given-names></name><name><surname>Nystrom</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Vitamin D as a protective factor in multiple sclerosis</article-title>. <source>Neurology</source>
<year>2012</year>; <volume>79</volume>: <fpage>2140</fpage>&#x02013;<lpage>2145</lpage>.<pub-id pub-id-type="pmid">23170011</pub-id></mixed-citation></ref><ref id="bibr6-2055217317727296"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>Aivo</surname><given-names>J</given-names></name><name><surname>Hongell</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the finnish maternity cohort</article-title>. <source>JAMA Neurol</source>
<year>2016</year>; <volume>73</volume>: <fpage>515</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">26953778</pub-id></mixed-citation></ref><ref id="bibr7-2055217317727296"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Ramagopalan</surname><given-names>S</given-names></name></person-group>
<article-title>The month of birth effect in multiple sclerosis: Systematic review, meta-analysis and effect of latitude</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2013</year>; <volume>84</volume>: <fpage>427</fpage>&#x02013;<lpage>432</lpage>.<pub-id pub-id-type="pmid">23152637</pub-id></mixed-citation></ref><ref id="bibr8-2055217317727296"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>S</given-names><suffix>Jr.</suffix></name><name><surname>Taylor</surname><given-names>B</given-names></name><name><surname>Blizzard</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<article-title>Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis</article-title>. <source>Ann Neurol</source>
<year>2010</year>; <volume>68</volume>: <fpage>193</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">20695012</pub-id></mixed-citation></ref><ref id="bibr9-2055217317727296"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mowry</surname><given-names>EM</given-names></name><name><surname>Krupp</surname><given-names>LB</given-names></name><name><surname>Milazzo</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis</article-title>. <source>Ann Neurol</source>
<year>2010</year>; <volume>67</volume>: <fpage>618</fpage>&#x02013;<lpage>624</lpage>.<pub-id pub-id-type="pmid">20437559</pub-id></mixed-citation></ref><ref id="bibr10-2055217317727296"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mowry</surname><given-names>EM</given-names></name><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><etal>et al.</etal></person-group>
<article-title>Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis</article-title>. <source>Ann Neurol</source>
<year>2012</year>; <volume>72</volume>: <fpage>234</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">22926855</pub-id></mixed-citation></ref><ref id="bibr11-2055217317727296"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correale</surname><given-names>J</given-names></name><name><surname>Ysrraelit</surname><given-names>MC</given-names></name><name><surname>Gaitan</surname><given-names>MI</given-names></name></person-group>
<article-title>Immunomodulatory effects of Vitamin D in multiple sclerosis</article-title>. <source>Brain</source>
<year>2009</year>; <volume>132</volume>: <fpage>1146</fpage>&#x02013;<lpage>1160</lpage>.<pub-id pub-id-type="pmid">19321461</pub-id></mixed-citation></ref><ref id="bibr12-2055217317727296"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adorini</surname><given-names>L</given-names></name><name><surname>Penna</surname><given-names>G</given-names></name></person-group>
<article-title>Control of autoimmune diseases by the vitamin D endocrine system</article-title>. <source>Nat Clin Pract Rheumatol</source>
<year>2008</year>; <volume>4</volume>: <fpage>404</fpage>&#x02013;<lpage>412</lpage>.<pub-id pub-id-type="pmid">18594491</pub-id></mixed-citation></ref><ref id="bibr13-2055217317727296"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolders</surname><given-names>J</given-names></name><name><surname>Menheere</surname><given-names>P</given-names></name><name><surname>Kessels</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2008</year>; <volume>14</volume>: <fpage>1220</fpage>&#x02013;<lpage>1224</lpage>.<pub-id pub-id-type="pmid">18653736</pub-id></mixed-citation></ref><ref id="bibr14-2055217317727296"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhalla</surname><given-names>AK</given-names></name><name><surname>Amento</surname><given-names>EP</given-names></name><name><surname>Serog</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<article-title>1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation</article-title>. <source>J Immunol</source>
<year>1984</year>; <volume>133</volume>: <fpage>1748</fpage>&#x02013;<lpage>1754</lpage>.<pub-id pub-id-type="pmid">6206136</pub-id></mixed-citation></ref><ref id="bibr15-2055217317727296"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Sims</surname><given-names>GP</given-names></name><name><surname>Chen</surname><given-names>XX</given-names></name><etal>et al.</etal></person-group>
<article-title>Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation</article-title>. <source>J Immunol</source>
<year>2007</year>; <volume>179</volume>: <fpage>1634</fpage>&#x02013;<lpage>1647</lpage>.<pub-id pub-id-type="pmid">17641030</pub-id></mixed-citation></ref><ref id="bibr16-2055217317727296"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonstra</surname><given-names>A</given-names></name><name><surname>Barrat</surname><given-names>FJ</given-names></name><name><surname>Crain</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<article-title>1Alpha,25-dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells</article-title>. <source>J Immunol</source>
<year>2001</year>; <volume>167</volume>: <fpage>4974</fpage>&#x02013;<lpage>4980</lpage>.<pub-id pub-id-type="pmid">11673504</pub-id></mixed-citation></ref><ref id="bibr17-2055217317727296"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotirchos</surname><given-names>ES</given-names></name><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Eckstein</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<article-title>Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis</article-title>. <source>Neurology</source>
<year>2016</year>; <volume>86</volume>: <fpage>382</fpage>&#x02013;<lpage>390</lpage>.<pub-id pub-id-type="pmid">26718578</pub-id></mixed-citation></ref><ref id="bibr18-2055217317727296"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname><given-names>S</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name><name><surname>Dosch</surname><given-names>HM</given-names></name><etal>et al.</etal></person-group>
<article-title>Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2011</year>; <volume>96</volume>: <fpage>2826</fpage>&#x02013;<lpage>2834</lpage>.<pub-id pub-id-type="pmid">21697250</pub-id></mixed-citation></ref><ref id="bibr19-2055217317727296"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolders</surname><given-names>J</given-names></name><name><surname>Peelen</surname><given-names>E</given-names></name><name><surname>Thewissen</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis</article-title>. <source>PloS One</source>
<year>2010</year>; <volume>5</volume>: <fpage>e15235</fpage>&#x02013;<lpage>e15235</lpage>.<pub-id pub-id-type="pmid">21179201</pub-id></mixed-citation></ref><ref id="bibr20-2055217317727296"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashtari</surname><given-names>F</given-names></name><name><surname>Toghianifar</surname><given-names>N</given-names></name><name><surname>Zarkesh-Esfahani</surname><given-names>SH</given-names></name><etal>et al.</etal></person-group>
<article-title>Short-term effect of high-dose vitamin D on the level of interleukin 10 in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial</article-title>. <source>Neuroimmunomodulation</source>
<year>2015</year>; <volume>22</volume>: <fpage>400</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">26401986</pub-id></mixed-citation></ref><ref id="bibr21-2055217317727296"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toghianifar</surname><given-names>N</given-names></name><name><surname>Ashtari</surname><given-names>F</given-names></name><name><surname>Zarkesh-Esfahani</surname><given-names>SH</given-names></name><etal>et al.</etal></person-group>
<article-title>Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial</article-title>. <source>J Neuroimmunol</source>
<year>2015</year>; <volume>285</volume>: <fpage>125</fpage>&#x02013;<lpage>128</lpage>.<pub-id pub-id-type="pmid">26198928</pub-id></mixed-citation></ref><ref id="bibr22-2055217317727296"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muris</surname><given-names>AH</given-names></name><name><surname>Smolders</surname><given-names>J</given-names></name><name><surname>Rolf</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<article-title>Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study</article-title>. <source>J Neuroimmunol</source>
<year>2016</year>; <volume>300</volume>: <fpage>47</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">27806875</pub-id></mixed-citation></ref><ref id="bibr23-2055217317727296"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aivo</surname><given-names>J</given-names></name><name><surname>Hanninen</surname><given-names>A</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta</article-title>. <source>J Neuroimmunol</source>
<year>2015</year>; <volume>280</volume>: <fpage>12</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">25773149</pub-id></mixed-citation></ref><ref id="bibr24-2055217317727296"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polman</surname><given-names>CH</given-names></name><name><surname>Reingold</surname><given-names>SC</given-names></name><name><surname>Banwell</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<article-title>Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria</article-title>. <source>Ann Neurol</source>
<year>2011</year>; <volume>69</volume>: <fpage>292</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">21387374</pub-id></mixed-citation></ref><ref id="bibr25-2055217317727296"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Chard</surname><given-names>DT</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name></person-group>
<article-title>Clinically isolated syndromes</article-title>. <source>Lancet Neurol</source>
<year>2012</year>; <volume>11</volume>: <fpage>157</fpage>&#x02013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">22265211</pub-id></mixed-citation></ref><ref id="bibr26-2055217317727296"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonergan</surname><given-names>R</given-names></name><name><surname>Kinsella</surname><given-names>K</given-names></name><name><surname>Fitzpatrick</surname><given-names>P</given-names></name><etal>et al.</etal></person-group>
<article-title>Multiple sclerosis prevalence in Ireland: Relationship to vitamin D status and HLA genotype</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2011</year>; <volume>82</volume>: <fpage>317</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">21248317</pub-id></mixed-citation></ref><ref id="bibr27-2055217317727296"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connell</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Kinsella</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: Study protocol for an exploratory randomized double-blind placebo-controlled trial</article-title>. <source>Trials</source>
<year>2013</year>; <volume>14</volume>: <fpage>272</fpage>&#x02013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">23981773</pub-id></mixed-citation></ref><ref id="bibr28-2055217317727296"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>AC</given-names></name><name><surname>Kelly</surname><given-names>S</given-names></name><name><surname>Basdeo</surname><given-names>SA</given-names></name><etal>et al.</etal></person-group>
<article-title>A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers</article-title>. <source>Mult Scler</source>
<year>2012</year>; <volume>18</volume>: <fpage>1797</fpage>&#x02013;<lpage>1800</lpage>.<pub-id pub-id-type="pmid">22457344</pub-id></mixed-citation></ref><ref id="bibr29-2055217317727296"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>Levin</surname><given-names>LI</given-names></name><name><surname>Hollis</surname><given-names>BW</given-names></name><etal>et al.</etal></person-group>
<article-title>Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis</article-title>. <source>JAMA</source>
<year>2006</year>; <volume>296</volume>: <fpage>2832</fpage>&#x02013;<lpage>2838</lpage>.<pub-id pub-id-type="pmid">17179460</pub-id></mixed-citation></ref><ref id="bibr30-2055217317727296"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Steele</surname><given-names>SU</given-names></name><name><surname>Waubant</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls</article-title>. <source>Mult Scler</source>
<year>2016</year>; <volume>22</volume>: <fpage>753</fpage>&#x02013;<lpage>760</lpage>.<pub-id pub-id-type="pmid">26286698</pub-id></mixed-citation></ref><ref id="bibr31-2055217317727296"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>JM</given-names></name><name><surname>Lalor</surname><given-names>SJ</given-names></name><name><surname>Sweeney</surname><given-names>CM</given-names></name><etal>et al.</etal></person-group>
<article-title>T cells in multiple sclerosis and experimental autoimmune encephalomyelitis</article-title>. <source>Clin Exp Immunol</source>
<year>2010</year>; <volume>162</volume>: <fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">20682002</pub-id></mixed-citation></ref><ref id="bibr32-2055217317727296"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolf</surname><given-names>L</given-names></name><name><surname>Muris</surname><given-names>AH</given-names></name><name><surname>Hupperts</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<article-title>Illuminating vitamin D effects on B-cells &#x02013; the multiple sclerosis perspective</article-title>. <source>Immunology</source>
<year>2016</year>; <volume>147</volume>: <fpage>275</fpage>&#x02013;<lpage>284</lpage>.<pub-id pub-id-type="pmid">26714674</pub-id></mixed-citation></ref><ref id="bibr33-2055217317727296"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prietl</surname><given-names>B</given-names></name><name><surname>Treiber</surname><given-names>G</given-names></name><name><surname>Mader</surname><given-names>JK</given-names></name><etal>et al.</etal></person-group>
<article-title>High-dose cholecalciferol supplementation significantly increases peripheral CD4(+) Tregs in healthy adults without negatively affecting the frequency of other immune cells</article-title>. <source>Eur J Nutr</source>
<year>2014</year>; <volume>53</volume>: <fpage>751</fpage>&#x02013;<lpage>759</lpage>.<pub-id pub-id-type="pmid">23999998</pub-id></mixed-citation></ref><ref id="bibr34-2055217317727296"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bscheider</surname><given-names>M</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group>
<article-title>Vitamin D immunoregulation through dendritic cells</article-title>. <source>Immunology</source>
<year>2016</year>; <volume>148</volume>: <fpage>227</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">27040466</pub-id></mixed-citation></ref><ref id="bibr35-2055217317727296"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghashut</surname><given-names>RA</given-names></name><name><surname>Talwar</surname><given-names>D</given-names></name><name><surname>Kinsella</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>The effect of the systemic inflammatory response on plasma vitamin 25 (OH) D concentrations adjusted for albumin</article-title>. <source>PloS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e92614</fpage>&#x02013;<lpage>e92614</lpage>.<pub-id pub-id-type="pmid">24667823</pub-id></mixed-citation></ref><ref id="bibr36-2055217317727296"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maverakis</surname><given-names>E</given-names></name><name><surname>Miyamura</surname><given-names>Y</given-names></name><name><surname>Bowen</surname><given-names>MP</given-names></name><etal>et al.</etal></person-group>
<article-title>Light, including ultraviolet</article-title>. <source>J Autoimmun</source>
<year>2010</year>; <volume>34</volume>: <fpage>J247</fpage>&#x02013;<lpage>J257</lpage>.<pub-id pub-id-type="pmid">20018479</pub-id></mixed-citation></ref><ref id="bibr37-2055217317727296"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>KC</given-names></name><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>Kochert</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b</article-title>. <source>JAMA Neurol</source>
<year>2015</year>; <volume>72</volume>: <fpage>1458</fpage>&#x02013;<lpage>1465</lpage>.<pub-id pub-id-type="pmid">26458124</pub-id></mixed-citation></ref><ref id="bibr38-2055217317727296"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascherio</surname><given-names>A</given-names></name><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>White</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<article-title>Vitamin D as an early predictor of multiple sclerosis activity and progression</article-title>. <source>JAMA Neurol</source>
<year>2014</year>; <volume>71</volume>: <fpage>306</fpage>&#x02013;<lpage>314</lpage>.<pub-id pub-id-type="pmid">24445558</pub-id></mixed-citation></ref><ref id="bibr39-2055217317727296"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolders</surname><given-names>J</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name><name><surname>Holm&#x000f8;y</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<article-title>High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing&#x02013;remitting multiple sclerosis receiving subcutaneous interferonB-1a</article-title>. <source>Mult Scler</source>
<year>2016</year>; <volume>22</volume>.</mixed-citation></ref><ref id="bibr40-2055217317727296"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Cassard</surname><given-names>S</given-names></name><name><surname>Steele</surname><given-names>SU</given-names></name><etal>et al.</etal></person-group>
<article-title>The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis</article-title>. <source>Contemp Clin Trials</source>
<year>2014</year>; <volume>39</volume>: <fpage>288</fpage>&#x02013;<lpage>293</lpage>.<pub-id pub-id-type="pmid">25311447</pub-id></mixed-citation></ref><ref id="bibr41-2055217317727296"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorr</surname><given-names>J</given-names></name><name><surname>Ohlraun</surname><given-names>S</given-names></name><name><surname>Skarabis</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): Study protocol for a randomized controlled trial</article-title>. <source>Trials</source>
<year>2012</year>; <volume>13</volume>: <fpage>15</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">22316314</pub-id></mixed-citation></ref></ref-list></back></article>